Rituximab: Infusion reaction treated with plasmapheresis: case report
However, the actual received dose was much smaller as the anaphylactic reaction occurred shortly after commencement of the infusion, which was immediately discontinued. Severe infections occurred in three patients, with one patient with agranulocytosis developing sepsis, and two patients had pneumonia ...
Initial management has been reduction in immunosuppression, but response to this is reported to be variable and low.63 Additional treatment strate- gies include antiviral therapy, interferon alpha, EBV-specific T-cell infusion, chemotherapy, and rituximab.62–65 The use of rituximab to treat PTLD,...
Intolerance was defined as any previous infusion-related severe reaction to rituximab requiring advanced care or delayed reactions such as serum sickness syndrome (defined by the presence of fever, rash, and arthralgias with onset as long as 1 month after the infusion). Sensitized patients in ...
Induction treatment was discontinued for 59 (11%) of 525 patients for the following reasons: haematological toxicity (n=38 [64%]), infection (n=10 [17%]), tumour lysis syndrome (n=3 [5%]), infusion-related reaction (n=2 [3%]), no response (n=1 Discussion The results of this ...
Nonresponders were patients whose active lesion scores increased, remained stable or improved less than 80% compared with baseline, as assessed 4 months after the first infusion. A relapse was defined as the reappearance of active lesions, for which a new cycle of rituximab was prescribed if ...
Less frequent events occurred only in one patient each and included grade 3 acute pancreatitis, grade 4 skin reaction (epidermolysis), grade 4 peripheral neuropathy and grade 3 infusion reaction. In all but two cases the local physician decided to discontinue per protocol treatment and addressed ...
malignances and autoimmune diseases. Some patients develop hypersensitivity reactions after the infusion. It is unknown the percentage of these which are due to an IgE allergic mechanism. Also, there is not a standardized desensitization protocol that allows us to induce tolerance to this drug in ...
Drug infusion reaction 1 (2) 1 (2) 4 (9) 4 (7) 0.36 Cancer 2 (5) 2 (3) 1 (2) 1 (2) 0.62 Gastric adenocarcinoma 1 (2) 1 (2) 0 (0) 0 (0) Breast carcinoma 1 (2) 1 (2) 0 (0) 0 (0) Rectal carcinoma 0 (0) 0 (0) 1 (2) 1 (2) Results for patients ...
In a prospective study, 15 patients with CD20+ mantle cell or follicular lymphoma, bone marrow involvement, and polymerase chain reaction (PCR)–detectable molecular rearrangement received 2 cycles of intensive chemotherapy, each of which was followed by infusion of a growth factor and 2 doses of...